Home blood pressure monitoring provides the most directly relevant data
In May 2026, Lilly reported that in a late-stage trial of adults with obesity or overweight and at least one weight-related comorbidity, the highest 12 mg dose of retatrutide produced 28.3% average weight loss over 80 weeks, and more than 45% of participants lost 30% or more of their body weight
Thanks to carnitine it is possible to reduce the tremendously annoying accumulated fats at a faster rate than that which can be achieved with exercise alone

Key differences between cagrilintide and semaglutide Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways, complementary effects Gastric emptying: Cagrilintide: Very strong effect (dramatic slowing) Semaglutide: Moderate effect Combined: Maximum slowing Appetite suppression: Cagrilintide: Works via amylin/calcitonin receptors Semaglutide: Works via GLP-1 receptors in brain Combined: Dual-pathway suppression Side effects: Cagrilintide: More nausea/GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Combined: Higher side effect risk but manageable Approval status: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved CagriSema combination: Phase 3 trials Weight loss monotherapy: Cagrilintide alone: 10-12% body weight loss Semaglutide alone: 10-15% body weight loss Combined: 15-25% body weight loss Why combining cagrilintide and semaglutide works synergistically The combination targets weight loss through multiple pathways

It also regulates glucose metabolism, making it suitable for diabetic and non-diabetic individuals
Peptides do not contain estrogen, progesterone, or testosterone